API CAS 865854-05-3 Tideglusib Raw Material Tideglusib Powder Tideglusib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Tideglusib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Tideglusib
• Name: Tideglusib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 865854-05-3
• Mf: C19h14n2o2s
• MW: 334.39
• Melting Point: 148-150
• Density: 1.393
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

API CAS 865854-05-3 Tideglusib Raw Material Tideglusib Powder Tideglusib

Product Description

Product Details

Product Name	Tideglusib
CAS NO.	865854-05-3
Purity	99%
Melting point	148-150 C
Appearance and shape	White powder

Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non-ATP-competitive glycogen synthase kinase 3 (GSK-3) inhibitor.. Other GSK inhibitors. There are few classes of GSK-inhibitors, including lithium (Martinez et al., 2011), the small peptide L803mts10, and members of the thiazolidinedione family, containing non-competitive inhibitors of GSK-3, such as TDZD-8.Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy.

Application&Function

Tideglusib was originally developed to treat Alzheimer's disease, but it was unexpectedly discovered that it can be used to regenerate damaged teeth. Tideglusib is an irreversible, non-ATP-competitive GSK-3β inhibitor with IC50 of 60 nM.On November 9, 2020, AMO pharma announced that the FDA has granted its investigational therapy AMO-02 (tideglusib) Rare Pediatric Disease (RPD) designation for the treatment of congenital myotonic dystrophy.

Specification